Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr111.70 SEK
Change Today +4.80 / 4.49%
Volume 3.0M
SOBI On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
OTC US
OTC US
As of 11:30 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Open
kr107.00
Previous Close
kr106.90
Day High
kr113.70
Day Low
kr107.00
52 Week High
04/24/15 - kr113.70
52 Week Low
10/16/14 - kr65.25
Market Cap
30.8B
Average Volume 10 Days
1.3M
EPS TTM
kr-0.99
Shares Outstanding
270.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; Xiapex for the treatment of Peyronie’s disease; and Yondelis for the treatment of a type of cancer. The company also offers Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. In addition, it provides Aloxi, Betapred, ChondroCelect, Collatamp, Cometriq, Defibrotide, Erwinase, Ferriprox, Fosinopril, Kepivance, Megestrol, Ruconest, and Willfact for the treatment of rare diseases. Further, the company’s rFVIIIFc and rFIXFc are development projects in pipeline for the treatment of hemophilia; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002 is in Phase I clinical trials. It also manufactures drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A. The company has an agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

600 Employees
Last Reported Date: 04/15/15

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.4M
Compensation as of Fiscal Year 2014.

swedish orphan biovitrum ab (SOBI) Key Developments

Sobi Reports Audited Earnings Results for the Year Ended December 31, 2014

Sobi reported audited earnings results for the year ended December 31, 2014. For the period, the company’s net sales were SEK 2,607 million against SEK 2,177 million a year ago. Net profit was SEK 268 million or SEK 1.01 per share against SEK 93 million or SEK 0.35 per share a year ago. Net debt was SEK 298 million against SEK 353 million a year ago.

Biogen Idec and Swedish Orphan Biovitrum AB Announce Positive Results from Hemophilia B Study

Biogen Idec Inc. and Swedish Orphan Biovitrum AB have announced positive results from the Kids B-LONG Phase III clinical study which evaluated the safety, efficacy and pharmacokinetics of ALPROLIX in children under age 12 with severe hemophilia B. ALPROLIX was generally well tolerated and no inhibitors (neutralizing antibodies that may interfere with the activity of the therapy) were detected during the study. In this study, once-weekly prophylactic dosing with ALPROLIX resulted in low bleeding rates. ALPROLIX is the only approved hemophilia B therapy with prolonged circulation in the body. The successful completion of Kids B-LONG supports applications for pediatric indications in several geographies and is an important step in seeking marketing authorization for ALPROLIX in Europe. The European Medicines Agency requires the inclusion of pediatric study data in the initial marketing application for a new hemophilia therapy. Interim results of the Kids B-LONG study helped support the US approval of ALPROLIX for use in children.

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Alprolix(R) Paediatric Study

Biogen Idec and Swedish Orphan Biovitrum AB (publ) announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix(R) [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia B. Alprolix was generally well tolerated and no inhibitors (neutralising antibodies that may interfere with the activity of the therapy) were detected during the study. In this study, once-weekly prophylactic dosing with Alprolix resulted in low bleeding rates. Alprolix is the only approved hemophilia B therapy with prolonged circulation in the body. The successful completion of Kids B-LONG supports applications for paediatric indications in several geographies and is an important step in seeking marketing authorisation for Alprolix in Europe. The European Medicines Agency requires the inclusion of paediatric study data in the initial marketing application for a new haemophilia therapy. Interim results of the Kids B-LONG study helped support the U.S. approval of Alprolix for use in children. Kids B-LONG investigated the safety, efficacy, and pharmacokinetics (measurement of the presence of the drug in a person's body over time) of Alprolix in previously treated children under age 12 with severe haemophilia B. The study's primary endpoint was to evaluate the occurrence of inhibitor development. Secondary endpoints included the overall and spontaneous annualised bleeding rates (ABR), which is the estimated number of yearly bleeding episodes, and the number of injections used to treat bleeding episodes. In the study, children treated prophylactically with Alprolix had an overall median ABR of 1.97. The median ABR for spontaneous joint bleeds was zero. Approximately 33% of participants in the study experienced zero bleeding episodes. Overall, 91.7% of bleeding episodes were controlled by one or two injections of Alprolix. The terminal half-life of Alprolix in the study was 66.5 hours for children under six and 70.3 hours for children six to less than 12 years of age. Additional analyses of the Kids B-LONG study are ongoing, and detailed results will be presented at a future scientific meeting. No inhibitors to Alprolix were detected during the study. Alprolix was generally well tolerated and no cases of serious allergic reactions or vascular thrombotic events were reported in any participants, all of whom had been previously treated with other commercially available factor IX products. No serious adverse events were determined by any investigator to be related to the drug. One adverse event, decreased appetite, was considered related to Alprolix treatment and was reported in one participant. No participant discontinued the study due to an adverse event after receiving Alprolix. The pattern of treatment-emergent adverse events reported was consistent with the population studied and generally consistent with results seen in adolescents and adults in the pivotal Phase 3 B-LONG study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr111.70 SEK +4.80

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.80 EUR +0.152
Oxford Biomedica PLC 11.50 GBp 0.00
Veloxis Pharmaceuticals A/S kr0.80 DKK -0.005
View Industry Companies
 

Industry Analysis

SOBI

Industry Average

Valuation SOBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.3x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit www.biovitrum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.